Embla Medical hf.
OSSFF
$4.15
-$0.15-3.49%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 928.69M | 896.78M | 873.51M | 857.82M | 854.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 928.69M | 896.78M | 873.51M | 857.82M | 854.89M |
| Cost of Revenue | 350.14M | 334.17M | 325.53M | 315.79M | 320.19M |
| Gross Profit | 578.56M | 562.61M | 547.98M | 542.03M | 534.70M |
| SG&A Expenses | 408.00M | 393.31M | 385.44M | 381.05M | 381.11M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 804.00M | 772.40M | 753.89M | 738.39M | 742.14M |
| Operating Income | 124.70M | 124.39M | 119.62M | 119.43M | 112.75M |
| Income Before Tax | 107.94M | 102.20M | 96.35M | 95.24M | 90.56M |
| Income Tax Expenses | 24.29M | 24.66M | 22.62M | 22.55M | 21.60M |
| Earnings from Continuing Operations | 83.65 | 77.54 | 73.73 | 72.69 | 68.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -310.00K | -404.00K | -595.00K | -510.00K | -682.00K |
| Net Income | 83.34M | 77.14M | 73.14M | 72.18M | 68.28M |
| EBIT | 124.70M | 124.39M | 119.62M | 119.43M | 112.75M |
| EBITDA | 152.96M | 147.25M | 142.15M | 142.00M | 136.92M |
| EPS Basic | 0.20 | 0.18 | 0.17 | 0.17 | 0.16 |
| Normalized Basic EPS | 0.16 | 0.15 | 0.14 | 0.14 | 0.13 |
| EPS Diluted | 0.20 | 0.18 | 0.17 | 0.17 | 0.16 |
| Normalized Diluted EPS | 0.16 | 0.15 | 0.14 | 0.14 | 0.13 |
| Average Basic Shares Outstanding | 1.70B | 1.70B | 1.69B | 1.70B | 1.70B |
| Average Diluted Shares Outstanding | 1.70B | 1.70B | 1.69B | 1.70B | 1.70B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |